Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Bone Marrow Transplantation

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bmt.1704799PMID 15665848
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced-intensity conditioning (RIC) regimens result in low prevalence of premature ovarian failure (POF) in women underwent hematopoietic stem-cell transplantation (HST)

  2004cited by this paper
• Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome.

  2004cited by this paper
• Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.

  2004cited by this paper
• Bone Marrow Transplantation for Severe Aplastic Anemia : Influence of Conditioning and Graft-Versus-Host Disease Prophylaxis Regimens on Outcome

  2003cited by this paper
• High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

  2002cited by this paper
• Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program.

  2002cited by this paper
• Autologous recovery following non-myeloablative unrelated donor bone marrow transplantation for severe aplastic anaemia

  2002cited by this paper
• Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low‐dose total body irradiation, cyclophosphamide and Campath

  2001cited by this paper
• Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers.

  2001cited by this paper
• Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation.

  2001cited by this paper
• Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation.

  2000cited by this paper
• Current Results of Bone Marrow Transplantation in Patients with Acquired Severe Aplastic Anemia

  2000cited by this paper
• Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy.

  1999cited by this paper
• Allogeneic stem cell transplantation for Fanconi Anaemia. Severe Aplastic Anaemia Working Party of the EBMT and EUFAR. European Group for Blood and Marrow Transplantation.

  1998cited by this paper
• EFFECT OF MATCHING OF CLASS I HLA ALLELES ON CLINICAL OUTCOME AFTER TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS FROM AN UNRELATED DONOR

  1998cited by this paper
• Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program.

  1998cited by this paper
• Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient.

  1998cited by this paper
• Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience.

  1996cited by this paper
• Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.

  1996cited by this paper
• Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors.

  1994cited by this paper
• Unrelated donor marrow transplants for severe acquired aplastic anemia.

  1992cited by this paper
• Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome.

  1992cited by this paper
• Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia.

  1991cited by this paper
• Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results.

  1989cited by this paper
• Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

  1980cited by this paper
• CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S

  1974cited by this paper

• High Overall and GVHD-Free Survival in Patients with Aplastic Anemia Receiving in vivo T-cell Depletion Transplants and Long-Term Complications.

  2020cites this paper
• Update of humanized animal disease models in studying Graft-versus-host disease

  2018cites this paper
• Hematopoietic stem cell transplantation in FANCJ/BRIP1 fanconi anemia

  2017cites this paper
• Fludarabine-based reduced intensity regimen for matched related donor hematopoietic stem cell transplantation in acquired severe aplastic anemia.

  2017cites this paper
• Transplantation de cellules souches hématopoïétiques périphériques partiellement déplétées en lymphocytes T chez les patients avec anémie aplastique sévère : excellents résultats et incidence élevée de chimérisme mixte

  2016cites this paper
• Low‐dose total‐body irradiation and alemtuzumab‐based reduced‐intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease

  2015cites this paper
• Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.

  2014cites this paper
• Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate-dose alemtuzumab-based conditioning.

  2014cites this paper
• Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia

  2013cites this paper
• Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18–40 years without an HLA-identical sibling and failing immunosuppression

  2013cites this paper
• Current concepts in the pathophysiology and treatment of aplastic anemia.

  2013cites this paper
• Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience

  2012cites this paper
• Antibodies in the Treatment of Aplastic Anemia

  2012cites this paper
• Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab

  2012cites this paper
• Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches

  2011cites this paper
• Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.

  2011cites this paper
• Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.

  2011cites this paper
• Analytic Review: Neurological Complications of Transplantation

  2011cites this paper
• Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors

  2010cites this paper
• Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia

  2010cites this paper
• Implications of CD34+ cell dose on clinical and haematological outcome of allo-SCT for acquired aplastic anaemia

  2010cites this paper
• Is it time for a change? The case for early application of unrelated allo-SCT for severe aplastic anemia

  2010cites this paper
• Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD

  2009cites this paper
• Acquired aplastic anemia in childhood.

  2009cites this paper
• Guidelines for the diagnosis and management of aplastic anaemia

  2009cites this paper
• Myelodysplasia and acute leukemia as late complications of marrow failure: future prospects for leukemia prevention.

  2009cites this paper
• Fludarabine‐based reduced intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with aplastic anemia and fungal infections

  2009cites this paper
• Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia

  2008cites this paper
• Stem Cell Transplantation for Marrow Failure

  2008cites this paper
• Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies

  2008cites this paper
• 95 Aplastic Anemia

  2008cites this paper
• Idiopathic Aplastic Anemia

  2008cites this paper
• Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia

  2008cites this paper
• Bone marrow transplantation in children with severe aplastic anemia using a conditioning regimen containing 3 Gy of total body irradiation, cyclophosphamide with or without antithymocyte globulin

  2007cites this paper
• Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia

  2007cites this paper
• Marked improvement of cardiac function early after non-myeloablative BMT in a heavily transfused patient with severe aplastic anemia and heart failure

  2007cites this paper
• Umbilical-cord blood cell transplantation conditioned with a reduced intensity-regimen is a practical salvage therapy for severe aplastic anemia refractory to immunosuppressive therapy with antithymocyte globulin/ciclosporin.

  2007cites this paper
• Treatment of acquired aplastic anemia.

  2007cites this paper
• An update on the management of severe idiopathic aplastic anaemia in children

  2007influential citation
• feasibility and Results of Bone Marrow Transplantation from an HLA-Mismatched Unrelated Donor for Children and Young Adults with Acquired Severe Aplastic Anemia

  2007cites this paper
• [Treatment of acquired severe aplastic anemia in pediatric patients with immunosuppression and allogeneic stem cell hematopoietic transplant].

  2007cites this paper
• Marrow transplantation for severe aplastic anemia with significant renal impairment

  2007cites this paper
• Allogeneic stem cell transplantation for aplastic anemia.

  2007cites this paper
• Tratamiento de anemia aplásica severa adquirida en pacientes pediátricos con inmunosupresión y trasplante alogénico de precursores hematopoiéticos

  2007cites this paper
• Graft failure and severe autoimmune haemolysis following fludarabine-based reduced-intensity matched unrelated donor bone marrow transplantation for severe aplastic anaemia: salvage by second transplant with conventional dose conditioning

  2006cites this paper
• Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia.

  2006cites this paper
• Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H)

  2006cites this paper
• Current concepts in the pathophysiology and treatment of aplastic anemia.

  2006cites this paper
• Regeneration adenovirus-spezifischer T-Zellen nach pädiatrischer Stammzelltransplantation

  2006cites this paper
• Immunotherapeutic and immunoregulatory drugs in haematologic malignancies.

  2006cites this paper
• Making therapeutic decisions in adults with aplastic anemia.

  2006cites this paper
• omparable Outcomes of Matched-Related and lternative Donor Stem Cell Transplantation or Pediatric Severe Aplastic Anemia

  2006cites this paper
• Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.

  2006cites this paper
• Outcome of bone marrow transplantation in acquired and inherited aplastic anaemia in the Republic of Ireland

  2005cites this paper
• Management of acquired aplastic anaemia.

  2005cites this paper
• Haematopoietic stem cell transplantation to treat aplastic anaemia

  2005cites this paper
• Approaches to graft‐vs‐host disease

  2005cites this paper